Other Significant Agreements - Additional Information (Details)
|
|
|
|
1 Months Ended |
12 Months Ended |
63 Months Ended |
|
Feb. 17, 2021
shares
|
Oct. 16, 2020
shares
|
Nov. 06, 2018
USD ($)
shares
|
Jan. 31, 2020
USD ($)
shares
|
Nov. 30, 2015
USD ($)
shares
|
Dec. 31, 2021
USD ($)
Milestone
shares
|
Dec. 31, 2020
USD ($)
shares
|
Dec. 31, 2018
USD ($)
|
Feb. 01, 2021
USD ($)
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
| Research and development |
|
|
|
|
|
$ 64,855,000
|
$ 73,981,000
|
|
|
| Stock issued, new issues | shares |
3,162,500
|
5,500,000
|
|
|
|
|
|
|
|
| Common Stock |
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
| Stock issued, new issues | shares |
|
|
|
|
|
3,162,500
|
5,500,000
|
|
|
| MD Anderson Cancer Center | Patent and Technology License Agreement |
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
| Remaining funding amount for patent-related costs under license agreement |
|
|
|
|
|
$ 0
|
|
|
|
| Number of days of prior written notice to terminate agreement |
|
|
|
|
|
180 days
|
|
|
|
| Number of milestones achieved | Milestone |
|
|
|
|
|
0
|
|
|
|
| Payments with respect to license agreement |
|
|
|
|
|
$ 0
|
$ 0
|
|
|
| MD Anderson Cancer Center | Patent and Technology License Agreement | Minimum |
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
| Patent costs |
|
|
|
|
|
|
|
|
$ 1,500,000
|
| MD Anderson Cancer Center | Patent and Technology License Agreement | Maximum |
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
| Contingent future payments upon achievement of certain development and regulatory approval milestones |
|
|
|
|
$ 11,900,000
|
|
|
|
|
| Contingent payments in cash or through issuance of equity |
|
|
|
|
4,400,000
|
|
|
|
|
| MD Anderson Cancer Center | Patent and Technology License Agreement | Maximum | Diagnostic Products |
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
| Contingent future payments upon achievement of certain development and regulatory approval milestones |
|
|
|
|
2,400,000
|
|
|
|
|
| MD Anderson Cancer Center | Patent and Technology License Agreement | Maximum | Therapeutic Products |
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
| Contingent future payments upon achievement of certain development and regulatory approval milestones |
|
|
|
|
9,500,000
|
|
|
|
|
| MD Anderson Cancer Center | Research Agreement |
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
| Research agreement extension of expiration year and month |
|
|
|
|
|
2021-02
|
|
|
|
| Research and development expense payment due year one |
|
|
|
|
1,000,000.0
|
|
|
|
|
| Research and development expense payment due year two through five |
|
|
|
|
$ 1,250,000
|
|
|
|
|
| Percentage of overhead charges on direct expenses |
|
|
|
|
25.00%
|
|
|
|
|
| Preferred stock shares issuable in year one under research agreement | shares |
|
|
|
|
200,000
|
|
|
|
|
| Preferred stock shares issuable in year two through five under research agreement | shares |
|
|
|
|
20,833
|
|
|
|
|
| Research agreement expiration date |
|
|
|
|
Dec. 31, 2019
|
|
|
|
|
| Research and development |
|
|
|
$ 1,200,000
|
|
|
|
|
|
| Research and development expense payment due |
|
|
|
|
$ 0
|
|
|
|
|
| Preferred stock shares issuable under research agreement | shares |
|
|
|
|
0
|
|
|
|
|
| MD Anderson Cancer Center | Research Agreement | Series B Redeemable Convertible Preferred Stock |
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
| Stock issued, new issues | shares |
|
|
|
62,500
|
|
|
|
|
|
| Expense recognized to estimate fair value of shares |
|
|
|
|
|
$ 0
|
0
|
|
|
| Kayla Therapeutics S.A.S | Kayla License Agreement |
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
| Number of days of prior written notice to terminate agreement |
|
|
|
|
|
30 days
|
|
|
|
| Payments with respect to license agreement |
|
|
|
|
|
$ 0
|
|
|
|
| Upfront payment paid in cash |
|
|
$ 6,500,000
|
|
|
|
|
|
|
| Acquired in-process research and development expense |
|
|
|
|
|
|
|
$ 8,100,000
|
|
| Cash payment related to acquired in-process research and development |
|
|
|
|
|
|
|
6,500,000
|
|
| Royalty term determination period after first commercial sale of such product in such country |
|
|
|
|
|
10 years
|
|
|
|
| Number of days of notice to terminate agreement upon material breach |
|
|
|
|
|
60 days
|
|
|
|
| Kayla Therapeutics S.A.S | Kayla License Agreement | Phase 1/2 Clinical Trial |
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
| Number of milestones achieved | Milestone |
|
|
|
|
|
0
|
|
|
|
| Non-refundable milestone payment in cash |
|
|
$ 15,000,000.0
|
|
|
|
|
|
|
| Non-refundable milestone payment in common stock | shares |
|
|
177,318
|
|
|
|
|
|
|
| Milestone payment |
|
|
|
|
|
|
$ 15,000,000.0
|
|
|
| Kayla Therapeutics S.A.S | Kayla License Agreement | Common Stock |
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
| Shares issued in consideration for license agreement | shares |
|
|
118,212
|
|
|
|
|
|
|
| Value of shares issued, acquired in process research and development |
|
|
|
|
|
|
|
$ 1,600,000
|
|
| Kayla Therapeutics S.A.S | Kayla License Agreement | Maximum | Phase 1/2 Clinical Trial |
|
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
| Obligated to make cash payments upon achievement of clinical and regulatory milestones |
|
|
$ 100,000,000.0
|
|
|
|
|
|
|
| Value of common stock shares payable upon achievement of clinical and regulatory milestones |
|
|
$ 13,000,000.0
|
|
|
|
|
|
|